Anti‐infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|47|3|346-355

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.47, Iss.3, 2018-02, pp. : 346-355

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Favorable response to composite treatment including infliximab in a case of granulomatous cheilitis with Crohn's disease

By  

THE JOURNAL OF DERMATOLOGY, Vol. 42, Iss. 6, 2015-06 ,pp. : 651-652

John Wiley & Sons Inc

Access to resources Recommend Favorite

Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease

By Geboes Karel   Rutgeerts Paul   Opdenakker Ghislain   Olson Allan   Patel Kamlesh   Wagner Carrie L.   Marano Colleen W.  

Current Medical Research and Opinion, Vol. 21, Iss. 11, 2005-11 ,pp. : 1741-1754

Informa Healthcare

Access to resources Recommend Favorite

Biologic dose tailoring in Crohn disease

By  

INTERNAL MEDICINE JOURNAL, Vol. 45, Iss. 2, 2015-02 ,pp. : 170-177

John Wiley & Sons Inc

Access to resources Recommend Favorite

Anti‐adipocyte antibody response in patients with non‐alcoholic fatty liver disease

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 5, 2015-05 ,pp. : 900-908

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of infliximab with adalimumab in 827 biologic‐naïve patients with Crohn's disease: a population‐based Danish cohort study

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 5, 2018-03 ,pp. : 596-604

John Wiley & Sons Inc

Access to resources Recommend Favorite